IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?
Tertiary lymphoid structures (TLS) are associated with anticancer immunity, but the mechanisms underpinning their formation remain poorly understood. Amisaki et al. have recently shown that IL-33 mediates ILC2 gut-tumoral migration and promotes TLS formation in pancreatic ductal adenocarcinoma (PDAC) by inducing group 2 innate lymphoid cell (ILC2) Ltb expression. This study highlights new potential therapeutic avenues to enhance immunotherapy.
Authors
- Charlotte Simpson
- Timotheus Y.F. Halim (ORCID: https://orcid.org/0000-0001-9773-0023)
- T. Yip (ORCID: https://orcid.org/0000-0001-7949-5090)
Institutions
- University of Cambridge (GB)
Publication Details
- Journal
- Trends in cancer
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.trecan.2025.03.003
- Citations
- 1
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Pancreatic Cancer UK
- Cancer Research UK